top of page
-post-ai-image-5863_edited.jpg

Discover a Breakthrough in Cancer Treatment: Is TIL Therapy Right for You?

SERVICES

WHAT IS TIL THERAPY?

​​​

​​Tumor-infiltrating lymphocyte (TIL) therapy is an innovative cancer treatment that harnesses your body’s immune system to combat cancer. This advanced cancer immunotherapy involves extracting TILs, special white blood cells, from your tumor. These cells naturally attack cancer cells but often need a boost to be effective. In TIL therapy, doctors grow millions of these cells in a laboratory. Once expanded, the TILs are infused back into your body to enhance your immune response against the cancer. This personalized cancer treatment has shown promising results, especially in patients with melanoma and other types of cancers.

 

By utilizing personalized cancer therapy, TIL Therapy provides a promising option for patients, especially those with advanced cancers resistant to traditional treatments.

​

​


 


​

    TIL THERAPY IS A FORM OF IMMUNOTHERAPY

Immunotherapy is a type of medical treatment that helps the body’s own immune system to fight off disease. It is based on the fundamentals of science, such as recognizing how the body’s natural defenses can be used to treat and prevent illnesses. Immunotherapy can be used to treat a variety of diseases, including cancer, allergies, and autoimmune disorders. It works by stimulating the body’s immune system to recognize and attack certain cells, while leaving healthy cells unharmed. This is achieved through the use of drugs, vaccines, and other therapeutic interventions. Immunotherapy is an important part of modern medicine and can be used to treat several conditions.

WHAT ARE THE BENEFITS & CHALLENGES

BENEFITS

TIL therapy is a type of immunotherapy that uses the patient’s own immune cells to fight cancer, while surgery, chemotherapy, radiation, and targeted therapy are mainly aimed at directly killing or shrinking the tumor. TIL therapy has some advantages over other treatments, such as:

CHALLENGES

However, TIL therapy also has some limitations and challenges, such as:

​​

TIL therapy is a highly individualized and labor-intensive treatment that faces several challenges for scaling up and commercializing, such as:

Benifits & Challenges

         TIL History

Discovery & Early Trials
1980s

Scientists found that immune cells called tumor-infiltrating lymphocytes (TILs) could be taken from tumors, grown in the lab, and reinfused to attack cancer.

Larger Studies & Durable Responses
2010s

Clinical studies showed TIL therapy could shrink tumors and produce long-lasting responses for some melanoma patients.

FDA Approval (Lifileucel / Amtagvi)
2024

The FDA approved lifileucel (Amtagvi), the first TIL product for unresectable or metastatic melanoma after prior PD‑1 therapy.

Technique Refinement
1990s–2000s

Labs improved TIL growth methods (using IL‑2 and better culture techniques), increasing cell yield and effectiveness.

First Phase III Randomized Trial
2022

The M14TIL phase III study showed TIL therapy improved progression-free survival compared to standard treatment in advanced melanoma.

Now — Expansion & Ongoing Research
2025

Researchers are testing TIL therapy in more solid tumors and combining it with checkpoint inhibitors to boost outcomes.

TREATMENT WITH TIL

 

  1. The patient undergoes a surgical biopsy or resection of the tumor to obtain tumor tissue that contains tumor-infiltrating lymphocytes (TILs).- T

  2. The tumor tissue is sent to a specialized laboratory, where the TILs are isolated and tested for their ability to recognize and kill the patient's tumor cells.

  3. The selected TILs are then stimulated and expanded in vitro with interleukin-2 (IL-2), a protein that promotes rapid TIL growth. This process can take several weeks and result in billions of TILs.

  4. The patient receives a short course of chemotherapy, and sometimes radiation therapy, to deplete their existing immune cells and make room for the new TILs. This also reduces the immune suppression caused by the tumor and enhances the effectiveness of the TILs.

  5. The patient receives the TIL infusion through a vein, along with high-dose IL-2 to support the survival and function of the TILs. The TILs then travel to the tumor site and begin attacking tumor cells.

  6. The patient is monitored for side effects and response to the treatment. The patient may receive additional treatments or supportive care as needed.

​

​

TIL TREATMENT OF SOLID TUMORS 

​​Why TIL therapy is promising for melanoma and other solid tumors
Melanoma has been the cancer where TIL therapy has shown the most consistent benefit so far. Because melanoma tumors often attract T cells naturally, doctors can often collect enough TILs to expand. Clinical studies show that a significant share of patients with advanced melanoma experience tumor shrinkage, and some reach complete remission (no detectable tumor). Researchers are now testing the approach in other solid tumors such as cervical, ovarian, lung, colorectal, pancreatic cancers, and mesothelioma.
 

How well does TIL therapy work?
 

Results vary by cancer type and patient group. For advanced melanoma, multiple clinical trials have shown meaningful response rates and some long-lasting remissions. In other cancers, early trials show encouraging responses in subsets of patients, but more research is needed to know who benefits most.
 

Why treating solid tumors is harder than blood cancers
 

There are several reasons solid tumors are more difficult targets:


• Immunosuppressive tumor microenvironment: Tumors can release proteins that “turn off” immune cells or attract cells that dampen immune response.
• Physical barriers: Dense scar-like tissue around the tumor (stroma) can block T cells from reaching tumor cells.
• Tumor diversity: Solid tumors often contain a mix of cells with different markers, making it harder for one T cell type to attack all tumor cells.
How doctors are trying to overcome these barriers
Researchers use several strategies to improve TIL therapy for solid tumors:
• Combining TILs with checkpoint inhibitors (drugs that release immune system “brakes”).
• Improving lab methods to produce stronger, more active T cells.
• Selecting patients whose tumors have the right features (enough TILs and helpful tumor markers).
• Testing combination approaches — for example, TILs plus targeted drugs or radiation to make tumors more visible to the immune system.
 

What to expect if you pursue TIL therapy
 

In general, patients undergo tumor collection surgery, a lab expansion period (weeks), a short course of lymphodepleting chemotherapy, then the TIL infusion and close monitoring. Hospitals watch for side effects such as low blood counts, fever, and in rare cases, strong immune reactions.
 

Who might be a good candidate?


• Advanced or metastatic solid tumor (melanoma is the best-studied example).
• A tumor that can be safely removed to harvest TILs.
• Not responded to standard treatments, or eligible for a clinical trial.
Practical considerations
• Timing: Growing cells takes a few weeks, so TIL therapy is better suited for patients whose cancer is not rapidly progressing during that time.
• Where it’s offered: TIL therapy is available at specialized cancer centers and through clinical trials. Ask your care team for centers that offer it.
• Costs & coverage: Insurance coverage is evolving; FDA-approved products for certain cancers may be covered, but patient costs can vary.
 

Questions to bring to your doctor


1. Am I a candidate for TIL therapy or a related clinical trial?
2. Can my tumor provide enough cells to grow TILs?
3. What side effects should I expect and how are they managed?
4. How long will it take from surgery to infusion?
5. Where can I get this treatment and who will coordinate my care?
 

Patient stories and outcomes
 

Some patients have seen shrinking tumors and long periods without disease progression after TIL therapy. Outcomes depend on the cancer type, prior treatments, and overall health. Patient stories can be powerful — consider adding short, anonymized testimonials or links to published case reports.
 

Next steps
 

If you’re interested in TIL therapy, ask your oncologist about eligibility and clinical trials. You can also contact specialized treatment centers that offer TIL programs. Use the contact form on this site to request information or to be connected with a specialist.
 

See the Sources section below for links to the research and trusted organizations behind this information.

​

Sources

​

​

​

​

​

​

​

​

​
 

 

 

​
 

CONTACT

GET IN TOUCH
 

If you or a loved one are exploring TIL Therapy and want to learn more, we’re here to help. Use the form below to ask questions, request more information, or understand whether Tumor-Infiltrating Lymphocyte (TIL) Therapy may be a treatment option worth discussing with your care team. While we do not provide medical advice, we aim to share clear, reliable information to help you make informed decisions about emerging cancer treatments.

Thanks for submitting!

bottom of page